Alpha Cognition Inc. announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 17/575,025, titled "Solid Forms of ALPHA-1062 Gluconate," which includes claims covering protection for crystalline solid forms of ALPHA-1062 and will bolster existing patents that the company holds. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.

This Notice of Allowance signifies a pivotal step forward in the company's journey and is the result of years of reliable research and development, conducted by Alpha Cognition's team of esteemed scientists, researchers, and medical experts. ALPHA-1062 represents a breakthrough in the neurology market, offering a novel approach to addressing the symptomatic treatment of Alzheimer?s Disease.